Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

(2016) Seok Jin Kim et al.   LANCET ONCOLOGY

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

(2015) Semra Paydas et al.   ANNALS OF HEMATOLOGY

Programmed cell death-1 inhibition in lymphoma

(2015) Eliza A Hawkes et al.   LANCET ONCOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

(2015) Young Wha Koh et al.   TUMOR BIOLOGY

The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastro­intestinal tract cancer: a systematic review and meta-analysis

(2015) Xia Zhang et al.   OncoTargets and Therapy

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

(2013) Omid Hamid et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

(2011) D. J. Andorsky et al.   CLINICAL CANCER RESEARCH

A review of human carcinogens—Part B: biological agents

(2009) Véronique Bouvard et al.   LANCET ONCOLOGY

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research

(2009) E. S. Jaffe   Hematology-American Society of Hematology Education Program